Systemic immunotherapy with micellar resiquimod-polymer conjugates triggers a robust antitumor response in a breast cancer model

Resiquimod is an immunopotent toll-like receptor 7/8 agonist with anti-tumor activity. Despite being potent against skin cancers, it’s poorly tolerated systemically due to toxicity. Integrating resiquimod into nanoparticles presents an avenue to circumvent the toxicity problem. Herein, the preparati...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Adv Healthc Mater
Autori principali: Kakwere, Hamilton, Zhang, Hua, Ingham, Elizabeth S., Nura-Raie, Marina, Tumbale, Spencer K., Allen, Riley, Tam, Sarah M., Wu, Bo, Liu, Cheng, Kheirolomoom, Azadeh, Fite, Brett Z., Ilovitsh, Asaf, Lewis, Jamal S., Ferrara, Katherine W.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8153207/
https://ncbi.nlm.nih.gov/pubmed/33646600
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/adhm.202100008
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi